In this Issue
Phase 2 Study of Oral Ketamine for Depression Lauded by Media and Sponsor, Yet Closer Look Reveals Underwhelming Results
UN World Drug Report Comments on ‘Developments Around Psychedelics’
Another Californian Psychedelic Policy Reform Bill Bites the Dust
First Look at Beckley’s IV Psilocin
Other Stories (inc. stories from Compass Pathways, MindBio, Apex Labs, Relmada Therapeutics, MindMed, Otsuka, Lundbeck, INVI MindHealth, Numinus Wellness, Lykos Therapeutics, Healing Realty Trust, MedBright AI, and others).
***
Sign-in or join Pα+ to continue reading…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Subscribe AnnuallySubscribe Monthly
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space✓ Regular articles and deep dives across psychedelic research, policy and business✓ Interviews with insiders✓ Monthly interactive database and commentary on psychedelic patents✓ Quick-take analysis of major developments✓ A Library of primers and explainers✓ Access to our full back catalogue
Learn more about Pα+
